In cancer treatment,
cardiotoxicity due to chemotherapy such as heart failure, arrhythmia,
hypertension are among the most important problems that cause difficulties. In
addition, with the increasing cancer survival rates, the long-term
cardiovascular health of patients has gained importance. While the
anthracycline group such as doxorubicin and epirubicin causes irreversible
cardiotoxicity depending on the cumulative dose, trastuzumab causes reversible
cardiotoxicity. In the fluoropyrimidine group, the most common cardiac side
effect is acute coronary spasm. Patients should be evaluated for cardiovascular
risk before starting treatment and should be followed up during treatment. In
case of cardiotoxicity, treatment should be arranged in accordance with guideline
recommendations.
Bu kitabın bölümleri bulunmamaktadır.
Atıf Sayısı :
